Is human cytomegalovirus a target in cancer therapy?

John Inge Johnsen; Ninib Baryawno; Cecilia Söderberg-Nauclér

doi:10.18632/oncotarget.383

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Is human cytomegalovirus a target in cancer therapy?

John Inge Johnsen _, Ninib Baryawno and Cecilia Söderberg-Nauclér

PDF | HTML | How to cite

Oncotarget. 2011; 2:1329-1338. https://doi.org/10.18632/oncotarget.383

Metrics: PDF 3070 views | HTML 3447 views | ?

Abstract

John Inge Johnsen¹, Ninib Baryawno¹ and Cecilia Söderberg-Nauclér²

¹ Childhood Cancer Research Unit, Department of Women´s and Children´s Health, Karolinska Institute, 171 76 Stockholm, Sweden

² Karolinska Institute, Department of Medicine, Center for Molecular Medicine, Karolinska University Hospital in Solna, 171 76 Stockholm, Sweden

Received: December 12, 2011; Accepted: December 15, 2011; Published: December 31, 2011;

Keywords: cancer, human cytomegalovirus

Correspondence:

John Inge Johnsen, email:

Abstract

Human cytomegalovirus (HCMV) is a herpesvirus that is prevalent in the human population. HCMV has recently been implicated in different cancer forms where it may provide mechanisms for oncogenic transformation, oncomodulation and tumour cell immune evasion. Moreover, antiviral treatment against HCMV has been shown to inhibit tumour growth in preclinical models. Here we describe the possible involvement of HCMV in cancer and discuss the potential molecular impact expression of HCMV proteins have on tumour cells and the surrounding tumour microenvironment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 383

Publication Alerts

Research Perspectives:

Is human cytomegalovirus a target in cancer therapy?

Abstract